Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785366 · ClinicalTrials.gov registry record · Phase 3
A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)
A Phase 3 study, sponsored by Sebela Women's Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT03785366: Completed Phase 3 study, sponsored by Sebela Women's Health.
NCT03785366 is a Phase 3 study that has completed, run by Sebela Women's Health. The registered enrollment target is 41 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03785366, a Phase 3 study, has completed, sponsored by Sebela Women's Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
Primary Outcome
Assess the relative bioavailability of observed systemic copper from VeraCept versus ParaGard based on Cmax
Interventions
- DRUG VeraCept
- DRUG ParaGard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-12-17 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 3 |
What the finished NCT03785366 record still lists
NCT03785366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which VeraCept is the first listed.
NCT03785366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03785366 about?
NCT03785366 is a clinical study titled "A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)". to Assess the Pharmacokinetic Properties of VeraCept® Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women
What is the current status of trial NCT03785366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2018-12-17. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT03785366?
The interventions under investigation include: VeraCept (DRUG), ParaGard (DRUG).
Who is sponsoring clinical trial NCT03785366?
This trial is sponsored by Sebela Women's Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03785366's enrollment target sits among peer trials
41 1877th of 2000 higher than 123 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI